SHAREHOLDER ALERT: Weiss Law Reminds AQUA, LPTX, CNCE, and ALBO Shareholders About Its Ongoing Investigations
NEW YORK, Feb. 6, 2023 /PRNewswire/ --
If you own shares in any of the companies listed above and
would like to discuss our investigations or have any questions concerning
this notice or your rights or interests, please contact:
Joshua Rubin, Esq.
Weiss Law
305 Broadway, 7th Floor
New York, NY 10007
(212) 682-3025
(888) 593-4771
[email protected]
Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Evoqua Water Technologies Corp. (NYSE: AQUA) in connection with the proposed acquisition of AQUA by Xylem Inc. ("Xylem"). Under the merger agreement, AQUA shareholders will receive 0.480 shares of Xylem common stock for each AQUA share, representing implied per-share consideration of $50.52 based upon Xylem's February 3, 2023 closing price of $105.25. If you own AQUA shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslaw.co/news-and-cases/aqua
Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Leap Therapeutics, Inc. (NASDAQ: LPTX), in connection with the proposed purchase of Flame Biosciences, Inc. ("Flame"). Under the terms of the merger agreement, LPTX will issue approximately 19,794,373 shares of its common stock and approximately 136,833 shares of a newly designated Series X non-voting convertible preferred stock to Flame shareholders. If you own : LPTX shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslaw.co/news-and-cases/lptx
Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Concert Pharmaceuticals, Inc. (NASDAQ: CNCE), in connection with the proposed acquisition of CNCE by Sun Pharmaceutical Industries Limited together with its subsidiaries and/or associated companies, "Sun Pharma", via tender offer. Under the terms of the merger agreement, CNCE shareholders will receive $8.00 in cash for each share of CNCE common stock owned, plus one non-tradeable contingent value right per share. If you own CNCE shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslaw.co/news-and-cases/cnce
Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Albireo Pharma, Inc. (NASDAQ: ALBO), in connection with the proposed acquisition of ALBO by Ipsen S.A. via tender offer. Under the terms of the merger agreement, ALBO shareholders will receive $42.00 in cash for each share of ALBO common stock owned, plus one contingent value right per share. If you own ALBO shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslaw.co/news-and-cases/albo
SOURCE Weiss Law
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article